AI isn't the future—it's now. Meet the Forbes 30 Under 30 revolutionaries harnessing machine learning to build robotic astronauts, cut off funding for terrorists, and turn anyone into a genius coder.This is the new class of innovators making history.See the full 2026 #ForbesUnder30 list: https://t.co/o5fMdPuFMs(Photography by Sebastian Nevols; Additional Photography by Guerin Blask) ...

Meet the leaders, founders, creators and innovators on the 2026 #ForbesOver50 Global list: https://t.co/7PYEbzNS7oThese women hail from 36 countries and territories and are leaving their marks on every sector of business, from aviation and architecture to minerals and mining.Several have broken records to become “the first” in a position; others have invented technological solutions and medical therapies that stand to help millions of lives.All are examples of resilience in an ever-changing global environme ...

Core Viewpoint - TGI Solar Power Group is positioned as a leader in sustainable technology and environmental real estate development, enhancing its visibility and influence through its role in Earth Week Miami 2026 [1] Group 1: Company Initiatives - TGI Solar Power Group has announced its role as a lead sponsor for Earth Week Miami 2026, showcasing its commitment to sustainability [1] - The company will serve as the Official Business Development and Marketing Partner for the event, indicating a strategic move to strengthen its market presence [1] Group 2: Event Details - Earth Week Miami 2026 is scheduled to take place from April 22-26, 2026, and is presented by The ECO Channel [1] - The event is recognized as the region's premier convergence point for sustainability, innovation, and global media, highlighting its significance in the industry [1]

I lead about 30 plus partnerships with about 3.5% million followers on LinkedIn who are fired about fired up about inclusion and creating a world that works for everyone. So very excited >> and we wanted to have this conversation because >> we were we do the same thing. >> Yeah.>> In a lot of ways, right. We are trying to empower the doers, the other people who are doing things, especially connecting disconnected networks >> so that everything we were talking about what's the name of our talk and I think it ...

Greetings everyone. It is time for ARCs big ideas 2026 and I'm pretty excited about it and I have to tell you right up front I'm standing on the shoulders of the research team and actually the marketing team and compliance and you know really almost all the teams at ARC uh especially Katie Keith and Walker who spent eight hours to 16 hours a day in the last few days to uh really make this the final push. So very happy to introduce it to you again.Uh and so I'll go very quickly uh through uh what hit me uh a ...

RT Hans C Nelson 🗽 (@HansCNelson)They said it was "impossible." Tesla just did it anyways. https://t.co/QfX8Lh2w6h ...

Last year DeepSeek became a byword for a new wave of Chinese innovation in artificial intelligence. There are three reasons Europe should embrace it https://t.co/jc7i5kk6RlIllustration: Simon Bailly https://t.co/V4ox98dMYK ...

BioLargo Conference Summary Company Overview - **Company Name**: BioLargo (OTCPK:BLGO) - **Industry**: Environmental technology and medical devices - **Focus**: Innovation in sustainable technologies and health solutions Key Points and Arguments Company Vision and Strategy - BioLargo has been innovating for 18 years, aiming to create impactful technologies for a greater good, encapsulated in their slogan "We make life better" [2][3] - The company operates like an incubator, investing in technical assets and guiding them through adoption cycles, focusing on sustainability and health [3][4] - BioLargo emphasizes a deep dive into technology to find markets, de-risk innovations, and partner for commercialization [3][5] Current Projects and Innovations - **Battery Technology**: Positioned as a game changer for long-duration energy storage, targeting a multi-trillion-dollar market [6][10] - **Cleara Medical**: Focused on infection control and wound care, with a $25 million investment over 13 years, now entering the adoption phase [6][12] - **Odor and VOC Technology**: Historically the most profitable asset, currently facing a lawsuit but expected to reposition positively [6][16] - **PFAS Technology**: Aiming to eliminate "forever chemicals," with the first installation operational and in the adoption cycle [7][23] Financial Insights - Current market cap is approximately $50 million, with a potential valuation of $200 million based on the company's assets and market position [10][11] - The company has about $4 million in the bank, with no toxic debt, and operates with low corporate overhead [10][11] - BioLargo has a pipeline of over $200 million worth of projects, indicating strong future revenue potential [7][8] Market Position and Competitive Edge - BioLargo claims unmatched technology that could transform markets globally, focusing on being number one in their respective fields [8][9] - The company has a diverse portfolio that allows for multiple revenue streams, reducing risk by not relying on a single asset [37][38] - The strategy includes leveraging partnerships for scaled manufacturing and distribution, particularly in the battery and medical device sectors [12][19] Regulatory and Market Challenges - Cleara Medical is currently a physician preference item and not yet eligible for reimbursement; the company is working on regulatory enhancements to achieve this [30][31] - The PFAS technology is in the early adoption phase, with significant demand expected, necessitating partnerships for scaling [23][24] Future Outlook - BioLargo is optimistic about the upcoming milestones, particularly with Cleara Medical and battery technology, which are expected to significantly enhance the company's valuation [36][37] - The company is focused on maintaining a low-risk profile while pursuing high-value opportunities in transformative technologies [38] Additional Important Information - The company has a strong team of engineers and scientists, with a focus on impactful innovation [4][5] - BioLargo's business model emphasizes not just selling products but also creating factories and infrastructure to support their technologies [11][12] - The company is actively seeking partnerships to enhance their market presence and operational capabilities [19][34] This summary encapsulates the key insights from the BioLargo conference, highlighting the company's strategic direction, current projects, financial health, and future opportunities.

Core Insights - The discussion at the ICR Conference 2026 highlighted NCR Voyix's commitment to leveraging AI and technology to enhance partner support and drive innovation in the restaurant industry [1] Company Overview - NCR Voyix Corporation (NYSE: VYX) is a prominent global provider of digital commerce solutions specifically tailored for the retail and restaurant sectors, with a strong emphasis on platform-led SaaS and service capabilities [7] - The company is headquartered in Atlanta, Georgia, and serves customers in over 30 countries worldwide [7] Leadership Profile - Benny Tadele, as Executive Vice President and President of Restaurants at NCR Voyix, has a proven track record in transitioning traditional business models to innovative SaaS solutions, significantly enhancing growth and operational efficiency [2] - Prior to his role at NCR Voyix, Tadele played a crucial role at ACI Worldwide, where he implemented SaaS models that improved customer value and drove substantial revenue growth [3] - Tadele holds advanced degrees in computational science and engineering from the Georgia Institute of Technology, equipping him with a strong foundation in tech-driven business models [4] Leadership Philosophy - Tadele is dedicated to mentorship and leadership development, advocating for transformational leadership to unlock potential and foster collective success [5] - He promotes a culture of continuous improvement and strategic risk-taking within teams, encouraging exploration of new growth avenues [5] Community Engagement - Residing in Atlanta, Tadele balances his professional life with community involvement, applying his leadership skills to promote growth and resilience in local initiatives [6]

Financial Data and Key Metrics Changes - In Q4 2025, sales increased by 3.8% excluding COVID testing sales, with adjusted earnings per share (EPS) of $1.50 reflecting a growth of 12% compared to the prior year [18] - Adjusted gross margin was 57.1% of sales, an increase of 20 basis points year-over-year, while adjusted operating margin rose to 25.8%, reflecting an increase of 150 basis points [18] - The company forecasts adjusted EPS for 2026 to be in the range of $5.55-$5.80, indicating a 10% growth at the midpoint [19] Business Line Data and Key Metrics Changes - Nutrition sales declined in Q4, impacted by market share loss and increased manufacturing costs, with a focus on reigniting volume growth through price and promotion initiatives [9][10] - Diagnostics sales decreased by 3.5% due to a decline in COVID testing, while Core Lab Diagnostics grew by 3.5%, achieving accelerating growth [11] - EPD (Established Pharmaceuticals Division) saw a 7% increase in sales, with double-digit growth in India and several Latin American and Middle Eastern countries [12] - Medical devices sales grew by 10.5%, driven by a 12% increase in continuous glucose monitors and strong performance in electrophysiology and structural heart segments [12][14] Market Data and Key Metrics Changes - The U.S. pediatric nutrition business faced challenges due to market share loss and increased price sensitivity among consumers [9][10] - Core Lab Diagnostics growth was 7% excluding China, reflecting durable demand globally [11] - EPD's growth was well-balanced across markets, with significant contributions from emerging markets [12] Company Strategy and Development Direction - The company aims to transition back to a more balanced growth profile, focusing on volume growth alongside price increases [10] - The acquisition of Exact Sciences is expected to enhance Abbott's position in the cancer diagnostics market, adding a high-growth business to its portfolio [8] - The company plans to launch at least eight new products in the nutrition segment over the next 12 months to support growth [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the nutrition business but expressed confidence in the ability to reignite volume growth and return to positive growth in the second half of 2026 [27] - The company expects continued momentum in most business segments, with a focus on innovation and operational excellence driving growth [8][29] - Management highlighted the importance of addressing price sensitivity and the need for a sustainable growth strategy in the nutrition segment [25][27] Other Important Information - The company anticipates a favorable impact from foreign exchange on full-year reported sales, estimated at around 1% [19] - The adjusted tax rate is forecasted to be in the range of 15%-16% for the year [19] Q&A Session Summary Question: Concerns about revenue growth guidance - Management acknowledged a slight reduction in top-line guidance primarily due to challenges in the nutrition business but maintained EPS guidance in line with consensus [23][24] Question: Insights on the EP product portfolio - Management emphasized the successful launch of the Vault PFA catheter and the strategic positioning of Abbott's EP portfolio, expecting to grow in line with market trends [34][39] Question: Guidance considerations and risk adjustments - Management explained that the guidance reflects a mix of stable growth in core segments and anticipated recovery in diagnostics, with a focus on maintaining high single-digit growth [42][45] Question: Continuous glucose monitor (CGM) growth expectations - Management projected continued strong growth in CGM sales, driven by market expansion opportunities and new product launches [50][56] Question: Capital allocation and M&A strategy - Management indicated a focus on integrating Exact Sciences post-acquisition, with potential for smaller tuck-in acquisitions in the future [69][70]